Hydrocortisone succinate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Hydrocortisone succinate is a corticosteroid used to treat severe allergic reactions, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematological disorders, neoplastic diseases, nervous system conditions, ophthalmic diseases, renal diseases, respiratory diseases, and rheumatic disorders.

Brand Names
Solu-cortef
Generic Name
Hydrocortisone succinate
DrugBank Accession Number
DB14545
Background

Not Available

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 462.539
Monoisotopic: 462.225368055
Chemical Formula
C25H34O8
Synonyms
  • Cortisol 21-(hydrogen succinate)
  • Cortisol succinate
  • Hydrocortisone hemisuccinate anhydrous
  • Hydrocortisone hydrogen succinate
  • Hydrocortisone succinate
  • Hydroxycortisone succinate

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofAcquired hemolytic anemias•••••••••••••••••• •••••••• •••• ••••••••••••••••
Adjunct therapy in management ofAcute gouty arthritis•••••••••••••••••• •••••••• •••• ••••••••••••••••
Management ofAnkylosing spondylitis (as)•••••••••••••••••• •••••••• •••• ••••••••••••••••
Management ofBerylliosis•••••••••••••••••• •••••••• •••• ••••••••••••••••
Management ofBullous dermatitis herpetiformis•••••••••••••••••• •••••••• •••• ••••••••••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbametapirThe serum concentration of Hydrocortisone succinate can be increased when it is combined with Abametapir.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Hydrocortisone succinate.
AbemaciclibThe metabolism of Abemaciclib can be increased when combined with Hydrocortisone succinate.
AcalabrutinibThe metabolism of Acalabrutinib can be increased when combined with Hydrocortisone succinate.
AcarboseThe risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Acarbose.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Hydrocortisone sodium succinate50LQB69S1Z125-04-2HHZQLQREDATOBM-CODXZCKSSA-M
Hydrocortisone succinate monohydrateLIU00Z1Z8483784-20-7AFLWPAGYTPJSEY-CODXZCKSSA-N
Active Moieties
NameKindUNIICASInChI Key
HydrocortisoneunknownWI4X0X7BPJ50-23-7JYGXADMDTFJGBT-VWUMJDOOSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
A-hydrocort Inj 1000mg/8mlPowder, for solution1 g / vialIntramuscular; IntravenousHospira Healthcare Ulc1993-12-312012-08-03Canada flag
A-hydrocort Inj 100mg/2mlPowder, for solution100 mg / vialIntramuscular; IntravenousHospira Healthcare Ulc1992-12-312012-08-03Canada flag
A-hydrocort Inj 250mg/2mlPowder, for solution250 mg / vialIntramuscular; IntravenousHospira Healthcare Ulc1992-12-312012-08-03Canada flag
A-hydrocort Inj 500mg/4mlPowder, for solution500 mg / vialIntramuscular; IntravenousHospira Healthcare Ulc1992-12-312012-08-03Canada flag
Hydrocortisone Sodium Succinate for InjectionPowder, for solution500 mg / vialIntramuscular; IntravenousTEVA Canada Limited1994-12-312018-04-30Canada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
A-hydrocortInjection, powder, lyophilized, for solution100 mg/2mLIntramuscular; IntravenousHospira, Inc.2006-12-142010-07-01US flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
IHV1VP592V
CAS number
2203-97-6
InChI Key
VWQWXZAWFPZJDA-CGVGKPPMSA-N
InChI
InChI=1S/C25H34O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1
IUPAC Name
4-{2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C

References

General References
Not Available
KEGG Drug
D01442
ChemSpider
15760
BindingDB
50016931
RxNav
21651
ChEBI
31677
ChEMBL
CHEMBL977
ZINC
ZINC000004097472
Wikipedia
Hydrocortisone_hemisuccinate

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedTreatmentSeptic Shock2
4CompletedTreatmentShock1
4CompletedTreatmentUlcerative Colitis1
4Not Yet RecruitingTreatmentSepsis / Septic Shock / Shock / Systemic Inflammatory Response Syndrome (SIRS)1
4RecruitingOtherAddison's Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous100 mg/2mL
Injection, powder, for solution100 mg
InjectionIntramuscular; Intravenous100 mg
InjectionIntramuscular; Intravenous
Powder, for solutionIntramuscular; Intravenous100 mg / vial
Powder, for solutionIntramuscular; Intravenous250 mg / vial
Powder, for solutionIntramuscular; Intravenous500 mg / vial
Powder100 mg/1vial
Powder, for solutionIntramuscular; Intravenous1 g / vial
Injection, powder, for solution
SolutionAuricular (otic)
Injection, powder, lyophilized, for solutionIntravenous100 mg
Injection, powder, for solutionIntramuscular; Intravascular100 mg/2mL
Injection, powder, for solutionIntramuscular; Intravascular1000 mg/8mL
Injection, powder, for solutionIntramuscular; Intravascular250 mg/2mL
Injection, powder, for solutionIntramuscular; Intravascular500 mg/4mL
Injection, powder, for solutionIntramuscular; Intravenous100 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous1000 mg/8mL
Injection, powder, for solutionIntramuscular; Intravenous250 mg/2mL
Injection, powder, for solutionIntramuscular; Intravenous500 mg/4mL
Injection, powder, for solutionIntramuscular; Intravenous100 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0653 mg/mLALOGPS
logP2.17ALOGPS
logP1.54Chemaxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.66Chemaxon
pKa (Strongest Basic)-2.8Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area138.2 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity117.44 m3·mol-1Chemaxon
Polarizability48.68 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004j-0004900000-e530faeb68007ef36ea0
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-003s-1009000000-52019723ed10df964359
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-002b-3525900000-842096195ef2b1ea2929
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0089-3009000000-9502a41e3c151e29e4c5
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dl-1925100000-63c659c826d00d1e15d3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-9004100000-e03286a590f5c34f5717
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-228.8830037
predicted
DarkChem Lite v0.1.0
[M+H]+226.7988037
predicted
DarkChem Lite v0.1.0
[M+Na]+225.8376037
predicted
DarkChem Lite v0.1.0

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Joellenbeck L, Qian Z, Zarba A, Groopman JD: Urinary 6 beta-hydroxycortisol/cortisol ratios measured by high-performance liquid chromatography for use as a biomarker for the human cytochrome P-450 3A4. Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec;1(7):567-72. [Article]
  2. Litt J. (2016). Litt's Drug eruption & reaction manual (22nd ed.). CRC Press LLc.
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Bauersachs J, Christ M, Ertl G, Michaelis UR, Fisslthaler B, Busse R, Fleming I: Cytochrome P450 2C expression and EDHF-mediated relaxation in porcine coronary arteries is increased by cortisol. Cardiovasc Res. 2002 Jun;54(3):669-75. [Article]
  2. Matoulkova P, Pavek P, Maly J, Vlcek J: Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35. doi: 10.1517/17425255.2014.878703. Epub 2014 Jan 23. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Freel EM, Shakerdi LA, Friel EC, Wallace AM, Davies E, Fraser R, Connell JM: Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33. doi: 10.1210/jc.2004-0379. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Freel EM, Shakerdi LA, Friel EC, Wallace AM, Davies E, Fraser R, Connell JM: Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab. 2004 Sep;89(9):4628-33. doi: 10.1210/jc.2004-0379. [Article]

Drug created at July 12, 2018 21:25 / Updated at February 20, 2024 23:55